![Alexander Blake](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Alexander Blake worked as a Senior Research Analyst at Raymond James & Associates, Inc. from 2018 to 2021.
Then, worked as an Analyst at Sofinnova Investments, Inc. from 2021 to 2024.
Later, worked as a Healthcare Analyst at Hudson Bay Capital Management LP from 2024 to 2025.
Education includes undergraduate degree from The University of North Carolina at Chapel Hill in 2004, and graduate and doctorate degrees from the University of Wisconsin.
Ehemalige bekannte Positionen von Alexander Blake
| Unternehmen | Position | Ende |
|---|---|---|
Hudson Bay Capital Management LP
 Hudson Bay Capital Management LP Investment ManagersFinance Hudson Bay Capital seeks to generate consistent, risk-adjusted returns through varying market conditions. They target traditional and non-traditional sources of alpha by employing multiple absolute return strategies, utilizing rigorous fundamental analysis, and seek to identify growth opportunities that are uncorrelated to each other and to market indices. | Analyst-Equity | 01.08.2025 |
Sofinnova Investments, Inc. (Investment Management)
 Sofinnova Investments, Inc. (Investment Management) Investment ManagersFinance Sofinnova-IM primary focuses on (i) private venture related investments or (ii) equity related investments in public securities. Investments are generally made in biotechnology, pharmaceuticals and related industries. For its Venture Funds, the firm seeks to build a diverse and risk mitigated portfolio across stage, geography and equity market exposure. For its Public Fund, Sofinnova-IM seeks to deliver absolute returns across market cycles with the goal of capitalizing on significant sector inefficiency in the Therapeutics industry while exercising valuation discipline and focusing on risk management. | Analyst-Equity | 01.04.2024 |
Raymond James & Associates, Inc.
 Raymond James & Associates, Inc. Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01.07.2021 |
Ausbildung von Alexander Blake
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
97
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Raymond James & Associates, Inc.
Raymond James & Associates, Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Hudson Bay Capital Management LP
Hudson Bay Capital Management LP Investment ManagersFinance Hudson Bay Capital seeks to generate consistent, risk-adjusted returns through varying market conditions. They target traditional and non-traditional sources of alpha by employing multiple absolute return strategies, utilizing rigorous fundamental analysis, and seek to identify growth opportunities that are uncorrelated to each other and to market indices. | Finance |
University of Wisconsin
 University of Wisconsin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sofinnova Investments, Inc. (Investment Management)
Sofinnova Investments, Inc. (Investment Management) Investment ManagersFinance Sofinnova-IM primary focuses on (i) private venture related investments or (ii) equity related investments in public securities. Investments are generally made in biotechnology, pharmaceuticals and related industries. For its Venture Funds, the firm seeks to build a diverse and risk mitigated portfolio across stage, geography and equity market exposure. For its Public Fund, Sofinnova-IM seeks to deliver absolute returns across market cycles with the goal of capitalizing on significant sector inefficiency in the Therapeutics industry while exercising valuation discipline and focusing on risk management. | Finance |
